CYTK
Cytokinetics Inc
62.30$
+0.5%
vs. previous close
Closing price · As of: Nov 3, 2026
Ownership
Ownership Structure
Who owns Cytokinetics Inc (CYTK)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 99.6% of the shares are freely tradable; institutional investors hold 118.8%.
Institutional ownership
?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
118.8%
Insiders
?Share of the stock held by the executives, founders and major shareholders of the company itself.
0.7%
Float
?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
99.6%
Short % of float
?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
21.2%
Shares Outstanding
?Total number of shares issued. Price times share count gives market cap.
139Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 14.45 | 20,094,362 | +21.4 | 06/30/2026 |
| T. Rowe Price Investment Management,Inc. | 13.46 | 18,718,498 | +6.8 | 06/30/2026 |
| Wellington Management Company LLP | 4.99 | 6,931,770 | -13.5 | 06/30/2026 |
| Vanguard Portfolio Management, LLC | 4.83 | 6,711,799 | +14.9 | 06/30/2026 |
| State Street Corp | 4.67 | 6,494,233 | +13.0 | 06/30/2026 |
| Vanguard Capital Management, LLC | 4.40 | 6,117,515 | +11.5 | 06/30/2026 |
| FMR Inc | 3.62 | 5,031,782 | -53.1 | 06/30/2026 |
| venBio Select Advisor LLC | 3.60 | 4,999,999 | +50.0 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| T. Rowe Price Capital Appreciation | 4.52 | 6,285,983 | +0.0 | 09/30/2026 |
| iShares Core S&P Mid-Cap ETF | 3.56 | 4,952,045 | +0.0 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Blum Robert I | President & CEO | 278,544 | 17,353,291 $ | Sep 15, 2026 | both |
| Malik Fady Ibraham | EVP Research & Development | 153,902 | 9,588,095 $ | Oct 20, 2026 | direct |
| Henderson John T | Director | 78,712 | 4,903,758 $ | Oct 16, 2026 | direct |
| Callos Andrew | EVP, Chief Commercial Officer | 58,555 | 3,647,977 $ | Aug 31, 2026 | direct |
| Wierenga Wendell | Director | 35,660 | 2,221,618 $ | Oct 16, 2026 | direct |
| Wysenski Nancy | Director | 34,089 | 2,123,745 $ | Oct 16, 2026 | direct |
| Harrington Robert Arthur | Director | 22,127 | 1,378,512 $ | Oct 16, 2026 | direct |
| Parshall B Lynne | Director | 10,784 | 671,843 $ | Sep 1, 2026 | direct |
| Kaye Edward M. MD | Director | 10,629 | 662,187 $ | Oct 16, 2026 | direct |
| Landry Robert E | Director | 8,184 | 509,863 $ | Sep 15, 2026 | direct |
| Daly James M | Director | 3,585 | 223,346 $ | Oct 16, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | Blum Robert I | President & CEO | Sell | 7,500 | 62.81 | 471,075 |
| Nov 2, 2026 | Blum Robert I | President & CEO | Other | 7,500 | 10.60 | 79,500 |
| Oct 20, 2026 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | 64.01 | 224,035 |
| Oct 20, 2026 | Malik Fady Ibraham | EVP Research & Development | Other | 3,500 | 7.80 | 27,300 |
| Oct 16, 2026 | Wysenski Nancy | Director | Other | 97 | 63.92 | 6,200 |
| Oct 16, 2026 | Kaye Edward M. MD | Director | Other | 195 | 63.92 | 12,464 |
| Oct 16, 2026 | Harrington Robert Arthur | Director | Other | 195 | 63.92 | 12,464 |
| Oct 16, 2026 | Daly James M | Director | Other | 195 | 63.92 | 12,464 |
| Oct 16, 2026 | Wierenga Wendell | Director | Other | 97 | 63.92 | 6,200 |
| Oct 16, 2026 | Henderson John T | Director | Other | 352 | 63.92 | 22,500 |
| Oct 12, 2026 | Blum Robert I | President & CEO | Sell | 7,500 | 62.88 | 471,600 |
| Oct 12, 2026 | Blum Robert I | President & CEO | Other | 7,500 | 10.60 | 79,500 |
| Oct 6, 2026 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | 61.38 | 214,830 |
| Oct 6, 2026 | Malik Fady Ibraham | EVP Research & Development | Other | 3,500 | 7.80 | 27,300 |
| Sep 28, 2026 | Blum Robert I | President & CEO | Sell | 7,500 | 65.46 | 490,950 |
| Sep 28, 2026 | Blum Robert I | President & CEO | Other | 7,500 | 10.60 | 79,500 |
| Sep 22, 2026 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | 68.29 | 239,015 |
| Sep 22, 2026 | Malik Fady Ibraham | EVP Research & Development | Other | 3,500 | 7.80 | 27,300 |
| Sep 15, 2026 | Landry Robert E | Director | Sell | 1,000 | 72.13 | 72,130 |
| Sep 15, 2026 | Blum Robert I | President & CEO | Sell | 97,926 | 69.33 | 6,789,210 |
| Sep 14, 2026 | Blum Robert I | President & CEO | Other | 97,926 | 0.00 | – |
| Sep 14, 2026 | Blum Robert I | President & CEO | Other | 1,350 | 0.00 | – |
| Sep 14, 2026 | Blum Robert I | President & CEO | Sell | 7,500 | 73.44 | 550,800 |
| Sep 14, 2026 | Blum Robert I | President & CEO | Other | 7,500 | 10.60 | 79,500 |
| Sep 11, 2026 | Landry Robert E | Director | Sell | 1,000 | 74.66 | 74,660 |
| Sep 8, 2026 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | 75.46 | 264,110 |
| Sep 8, 2026 | Malik Fady Ibraham | EVP Research & Development | Other | 3,500 | 7.80 | 27,300 |
| Sep 1, 2026 | Parshall B Lynne | Director | Sell | 5,000 | 71.48 | 357,400 |
| Aug 31, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 10,000 | 70.24 | 702,400 |
| Aug 31, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Other | 10,000 | 23.26 | 232,600 |
| Aug 31, 2026 | Blum Robert I | President & CEO | Sell | 7,500 | 70.24 | 526,800 |
| Aug 31, 2026 | Blum Robert I | President & CEO | Other | 7,500 | 10.60 | 79,500 |
| Aug 18, 2026 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | 75.82 | 265,370 |
| Aug 18, 2026 | Malik Fady Ibraham | EVP Research & Development | Other | 3,500 | 7.80 | 27,300 |
| Aug 10, 2026 | Blum Robert I | President & CEO | Sell | 7,500 | 76.76 | 575,700 |
| Aug 10, 2026 | Blum Robert I | President & CEO | Other | 7,500 | 10.60 | 79,500 |
| Jul 30, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | 14,000 | 79.88 | 1,118,320 |
| Jul 30, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Other | 14,000 | 23.26 | 325,640 |
| Jul 27, 2026 | Blum Robert I | President & CEO | Sell | 7,500 | 80.87 | 606,525 |
| Jul 27, 2026 | Blum Robert I | President & CEO | Other | 7,500 | 10.60 | 79,500 |
| Jul 21, 2026 | Malik Fady Ibraham | EVP Research & Development | Sell | 3,500 | 80.59 | 282,065 |
| Jul 21, 2026 | Malik Fady Ibraham | EVP Research & Development | Other | 3,500 | 7.80 | 27,300 |
| Jul 15, 2026 | Wysenski Nancy | Director | Other | 75 | 82.62 | 6,197 |
| Jul 15, 2026 | Wierenga Wendell | Director | Other | 75 | 82.62 | 6,197 |
| Jul 15, 2026 | Kaye Edward M. MD | Director | Other | 151 | 82.62 | 12,476 |
| Jul 15, 2026 | Henderson John T | Director | Other | 272 | 82.62 | 22,473 |
| Jul 15, 2026 | Harrington Robert Arthur | Director | Other | 151 | 82.62 | 12,476 |
| Jul 15, 2026 | Daly James M | Director | Other | 151 | 82.62 | 12,476 |
| Jul 13, 2026 | Blum Robert I | President & CEO | Sell | 7,490 | 82.02 | 614,330 |
| Jul 13, 2026 | Blum Robert I | President & CEO | Other | 7,490 | 10.60 | 79,394 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.